Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure Treatment

Background: Cardiovascular disease (CVD) remains the leading cause of black-white morbidity and mortality disparities in the United States. Objectives : We sought to compare black-white CVD morbidity and mortality if lipid and blood pressure treatments were prescribed to achieve targeted lipid and b...

Full description

Bibliographic Details
Main Authors: Sanjay Basu MD, PhD, Jeremy B. Sussman MD, MS, Rodney A. Hayward MD
Format: Article
Language:English
Published: SAGE Publishing 2017-08-01
Series:MDM Policy & Practice
Online Access:https://doi.org/10.1177/2381468317725741
id doaj-5b65d0ab79d54b73be9c3307821d68e4
record_format Article
spelling doaj-5b65d0ab79d54b73be9c3307821d68e42020-11-25T03:13:24ZengSAGE PublishingMDM Policy & Practice2381-46832017-08-01210.1177/2381468317725741Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure TreatmentSanjay Basu MD, PhDJeremy B. Sussman MD, MSRodney A. Hayward MDBackground: Cardiovascular disease (CVD) remains the leading cause of black-white morbidity and mortality disparities in the United States. Objectives : We sought to compare black-white CVD morbidity and mortality if lipid and blood pressure treatments were prescribed to achieve targeted lipid and blood pressure levels (treat-to-target [TTT]) or personalized CVD risk and treatment benefit estimates (benefit-based tailored treatment [BTT]). Methods: We utilized a microsimulation model of statin and blood pressure treatment based on a TTT approach (Joint National Commission 7; Adult Treatment Panel III) or a BTT approach (treating those with 10-year CVD risk ≥10%, a modification and extension of recent American College of Cardiology/American Heart Association guidelines). We input data from the National Health and Nutrition Examination Survey, isolating adults 40 to 75 years of age without prior CVD events. Results: We observed that TTT would prevent fewer CVD events (17.0 events prevented per 1,000 whites, 22.2 per 1,000 blacks) than the BTT approach (25.9 events prevented per 1,000 whites, 45.4 per 1,000 blacks). TTT could lower the national black-white CVD event rate disparity from 23.1 excess events per 1,000 blacks to 17.9 excess events (−23%), while BTT could lower the disparity to 3.6 excess events (−84% overall). The inferiority of TTT to BTT remained consistent in sensitivity analyses testing alternative treatment targets and either over- or underestimation of risk by commonly used equations. Conclusions: A BTT approach to lipid and blood pressure treatment would be expected to prevent more CVD events in the overall population and more effectively reduce national black-white CVD disparities than a traditional TTT approach.https://doi.org/10.1177/2381468317725741
collection DOAJ
language English
format Article
sources DOAJ
author Sanjay Basu MD, PhD
Jeremy B. Sussman MD, MS
Rodney A. Hayward MD
spellingShingle Sanjay Basu MD, PhD
Jeremy B. Sussman MD, MS
Rodney A. Hayward MD
Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure Treatment
MDM Policy & Practice
author_facet Sanjay Basu MD, PhD
Jeremy B. Sussman MD, MS
Rodney A. Hayward MD
author_sort Sanjay Basu MD, PhD
title Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure Treatment
title_short Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure Treatment
title_full Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure Treatment
title_fullStr Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure Treatment
title_full_unstemmed Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure Treatment
title_sort black-white cardiovascular disease disparities after target-based versus personalized benefit–based lipid and blood pressure treatment
publisher SAGE Publishing
series MDM Policy & Practice
issn 2381-4683
publishDate 2017-08-01
description Background: Cardiovascular disease (CVD) remains the leading cause of black-white morbidity and mortality disparities in the United States. Objectives : We sought to compare black-white CVD morbidity and mortality if lipid and blood pressure treatments were prescribed to achieve targeted lipid and blood pressure levels (treat-to-target [TTT]) or personalized CVD risk and treatment benefit estimates (benefit-based tailored treatment [BTT]). Methods: We utilized a microsimulation model of statin and blood pressure treatment based on a TTT approach (Joint National Commission 7; Adult Treatment Panel III) or a BTT approach (treating those with 10-year CVD risk ≥10%, a modification and extension of recent American College of Cardiology/American Heart Association guidelines). We input data from the National Health and Nutrition Examination Survey, isolating adults 40 to 75 years of age without prior CVD events. Results: We observed that TTT would prevent fewer CVD events (17.0 events prevented per 1,000 whites, 22.2 per 1,000 blacks) than the BTT approach (25.9 events prevented per 1,000 whites, 45.4 per 1,000 blacks). TTT could lower the national black-white CVD event rate disparity from 23.1 excess events per 1,000 blacks to 17.9 excess events (−23%), while BTT could lower the disparity to 3.6 excess events (−84% overall). The inferiority of TTT to BTT remained consistent in sensitivity analyses testing alternative treatment targets and either over- or underestimation of risk by commonly used equations. Conclusions: A BTT approach to lipid and blood pressure treatment would be expected to prevent more CVD events in the overall population and more effectively reduce national black-white CVD disparities than a traditional TTT approach.
url https://doi.org/10.1177/2381468317725741
work_keys_str_mv AT sanjaybasumdphd blackwhitecardiovasculardiseasedisparitiesaftertargetbasedversuspersonalizedbenefitbasedlipidandbloodpressuretreatment
AT jeremybsussmanmdms blackwhitecardiovasculardiseasedisparitiesaftertargetbasedversuspersonalizedbenefitbasedlipidandbloodpressuretreatment
AT rodneyahaywardmd blackwhitecardiovasculardiseasedisparitiesaftertargetbasedversuspersonalizedbenefitbasedlipidandbloodpressuretreatment
_version_ 1724647018273439744